I wouldn't be too hasty, RXP has a nasty history of underperforming out of nowhere. Certainly, it looks like delivering results in line with guidance is more likely, but in my opinion it'll take at least 2 reporting seasons of confirming that the indicative quarters are indeed realistic for it to reprice.